GRACE THERAPEUTICS INC (GRCE) Fundamental Analysis & Valuation

NASDAQ:GRCE • US00439U1043

Current stock price

3.57 USD
+0.24 (+7.21%)
At close:
3.69 USD
+0.12 (+3.36%)
After Hours:

This GRCE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. GRCE Profitability Analysis

1.1 Basic Checks

  • In the past year GRCE has reported negative net income.
  • GRCE had a negative operating cash flow in the past year.
  • GRCE had negative earnings in each of the past 5 years.
  • GRCE had a negative operating cash flow in each of the past 5 years.
GRCE Yearly Net Income VS EBIT VS OCF VS FCFGRCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • GRCE has a better Return On Assets (-8.73%) than 69.79% of its industry peers.
  • The Return On Equity of GRCE (-9.21%) is better than 76.04% of its industry peers.
Industry RankSector Rank
ROA -8.73%
ROE -9.21%
ROIC N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
GRCE Yearly ROA, ROE, ROICGRCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GRCE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRCE Yearly Profit, Operating, Gross MarginsGRCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. GRCE Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, GRCE has more shares outstanding
  • The number of shares outstanding for GRCE has been increased compared to 5 years ago.
  • There is no outstanding debt for GRCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRCE Yearly Shares OutstandingGRCE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
GRCE Yearly Total Debt VS Total AssetsGRCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 3.72 indicates that GRCE is not in any danger for bankruptcy at the moment.
  • GRCE's Altman-Z score of 3.72 is fine compared to the rest of the industry. GRCE outperforms 70.83% of its industry peers.
  • There is no outstanding debt for GRCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.72
ROIC/WACCN/A
WACCN/A
GRCE Yearly LT Debt VS Equity VS FCFGRCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 14.96 indicates that GRCE has no problem at all paying its short term obligations.
  • GRCE has a better Current ratio (14.96) than 89.06% of its industry peers.
  • A Quick Ratio of 14.96 indicates that GRCE has no problem at all paying its short term obligations.
  • GRCE's Quick ratio of 14.96 is amongst the best of the industry. GRCE outperforms 89.06% of its industry peers.
Industry RankSector Rank
Current Ratio 14.96
Quick Ratio 14.96
GRCE Yearly Current Assets VS Current LiabilitesGRCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GRCE Growth Analysis

3.1 Past

  • GRCE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.21%, which is quite impressive.
EPS 1Y (TTM)70.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 31.44% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-43.32%
EPS Next 2Y-9.59%
EPS Next 3Y6.98%
EPS Next 5Y31.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRCE Yearly Revenue VS EstimatesGRCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M
GRCE Yearly EPS VS EstimatesGRCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. GRCE Valuation Analysis

4.1 Price/Earnings Ratio

  • GRCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRCE Price Earnings VS Forward Price EarningsGRCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRCE Per share dataGRCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.59%
EPS Next 3Y6.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GRCE Dividend Analysis

5.1 Amount

  • GRCE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GRCE Fundamentals: All Metrics, Ratios and Statistics

GRACE THERAPEUTICS INC

NASDAQ:GRCE (4/8/2026, 8:00:02 PM)

After market: 3.69 +0.12 (+3.36%)

3.57

+0.24 (+7.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)06-26
Inst Owners23.67%
Inst Owner ChangeN/A
Ins Owners3.21%
Ins Owner ChangeN/A
Market Cap55.23M
Revenue(TTM)N/A
Net Income(TTM)-5.98M
Analysts82.5
Price Target11.73 (228.57%)
Short Float %14.74%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.59%
Min EPS beat(2)50.98%
Max EPS beat(2)68.2%
EPS beat(4)4
Avg EPS beat(4)64.31%
Min EPS beat(4)6.42%
Max EPS beat(4)131.63%
EPS beat(8)7
Avg EPS beat(8)46.23%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.43%
EPS NQ rev (1m)25.76%
EPS NQ rev (3m)30%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 3.53
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS4.19
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.73%
ROE -9.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.96
Quick Ratio 14.96
Altman-Z 3.72
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y-43.32%
EPS Next 2Y-9.59%
EPS Next 3Y6.98%
EPS Next 5Y31.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.02%
EBIT Next 3Y1.32%
EBIT Next 5Y23.12%
FCF growth 1Y35.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.61%
OCF growth 3YN/A
OCF growth 5YN/A

GRACE THERAPEUTICS INC / GRCE Fundamental Analysis FAQ

What is the fundamental rating for GRCE stock?

ChartMill assigns a fundamental rating of 3 / 10 to GRCE.


What is the valuation status for GRCE stock?

ChartMill assigns a valuation rating of 0 / 10 to GRACE THERAPEUTICS INC (GRCE). This can be considered as Overvalued.


Can you provide the profitability details for GRACE THERAPEUTICS INC?

GRACE THERAPEUTICS INC (GRCE) has a profitability rating of 1 / 10.


What is the expected EPS growth for GRACE THERAPEUTICS INC (GRCE) stock?

The Earnings per Share (EPS) of GRACE THERAPEUTICS INC (GRCE) is expected to decline by -43.32% in the next year.